Related Experiment Video
Updated: Jul 10, 2026
10:25
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
Published on: February 19, 2019
Hepatitis B and end-stage liver disease
Ilan S Weisberg1, Robert S Brown, Samuel H Sigal
1Division of Gastroenterology and Hepatology, New York Weill Cornell Medical Center, 525 E. 68th Street, New York, NY 10021, USA.
Clinics in Liver Disease
|November 6, 2007
Summary
Hepatitis B virus (HBV) infection can lead to severe liver disease. Recent advancements offer improved prevention and treatment options for HBV-related end-stage liver disease and cirrhosis.
Area of Science:
- Hepatology
- Virology
- Gastroenterology
Background:
- Hepatitis B virus (HBV) is a leading cause of chronic hepatitis and end-stage liver disease globally.
- Early-life HBV infection can result in cirrhosis, liver failure, or hepatocellular carcinoma in up to 40% of cases.
- Treatment options for HBV-related end-stage liver disease were historically limited.
Purpose of the Study:
- To review recent advances in the understanding of HBV-related end-stage liver disease.
- To highlight progress in the prevention and medical management of this condition.
- To provide an overview of the natural history of HBV-related liver disease.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of data on HBV natural history.
- Synthesis of information on prevention strategies and treatment modalities.
Main Results:
- Significant strides have been made in the past 15 years in managing hepatitis B cirrhosis.
- Current understanding of HBV natural history has improved.
- Newer prevention and treatment strategies are available.
Conclusions:
- Advances in prevention and treatment have expanded options for patients with HBV-related end-stage liver disease.
- Continued research is crucial for further improving outcomes.
- Effective management strategies can mitigate the progression to severe liver complications.
Related Concept Videos
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:24Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...